FDA Moves to Ease Restrictions on Gay Men Giving Blood
THURSDAY, Dec. 1, 2022 (HealthDay News) — U.S. Food & Drug Administration policies that have limited blood donations from men who have sex with men may soon ease.At the moment, FDA policy does not allow blood donation from men who have had sex with o…
Learn MoreFDA Moves to Ease Restrictions on Gay Men Giving Blood
THURSDAY, Dec. 1, 2022 (HealthDay News) – U.S. Food & Drug Administration policies that have limited blood donations from men who have sex with men may soon ease.At the moment, FDA policy does not allow blood donation from men who have had sex with ot…
Learn MoreUna segunda muerte en un ensayo sobre un medicamento experimental para el Alzheimer es preocupante
MARTES, 29 de noviembre de 2022 (HealthDay News) — Ya han muerto dos personas por hemorragias en el cerebro que podrían estar vinculadas con un medicamento experimental para el Alzheimer, lo que pone en duda la seguridad del fármaco.Una mujer de 65 a…
Learn MoreSix Additional Weeks of Rivaroxaban Reduces Recurrent VTE
WEDNESDAY, Nov. 30, 2022 (HealthDay News) — For patients with isolated distal deep venous thrombosis (DVT), six additional weeks of rivaroxaban after an initial six-week course of treatment reduces the risk for recurrent venous thromboembolism, accor…
Learn MoreCausal Effect Observed for Diastolic Blood Pressure on Neuroticism
WEDNESDAY, Nov. 30, 2022 (HealthDay News) — Diastolic blood pressure has a causal effect on neuroticism, but not on other psychological states of anxiety, depressive symptoms, or subjective well-being, according to a study published online Nov. 21 in…
Learn MoreSecond Death in Trial of Experimental Alzheimer’s Drug Is Raising Concerns
TUESDAY, Nov. 29, 2022 (HealthDay News) — Two people have now died from brain hemorrhages that may be linked to an experimental Alzheimer’s drug, calling into question the medication’s safety.A 65-year-old woman with early-stage Alzheimer’s recently …
Learn MoreLa FDA aprueba una terapia genética para la hemofilia que cuesta 3.5 millones de dólares
MIÉRCOLES, 23 de noviembre de 2022 (HealthDay News) — Las personas con una forma de hemofilia, un trastorno genético de la sangre, tienen ahora un tratamiento, que se administra una sola vez, que cuesta 3.5 millones de dólares.La Administración de Al…
Learn MoreFDA Approves First Gene Therapy for Adults With Hemophilia B
MONDAY, Nov. 28, 2022 (HealthDay News) — The U.S. Food and Drug Administration has approved Hemgenix (etranacogene dezaparvovec) for the treatment of hemophilia B in adults.Hemgenix, an adeno-associated virus vector-based gene therapy, is administere…
Learn MoreA Gene Therapy for Hemophilia That Costs $3.5 Million Gets FDA Approval
WEDNESDAY, Nov. 23, 2022 (HealthDay News) — People with one form of the genetic blood disorder hemophilia now have a one-time treatment with a $3.5 million price tag.The U.S. Food and Drug Administration approved the new gene therapy Hemgenix on Nov….
Learn MoreFive-Year Relative Survival 59.6 Percent in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Nov. 23, 2022 (HealthDay News) — About 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the British Journal of Haematology.Krzysztof Mąd…
Learn More